BACKGROUND: Inadequate response to antidepressant monotherapy in women with major depressive disorder is common. Testosterone administration has been shown to be an effective augmentation therapy in depressed hypogonadal men with selective serotonin reuptake inhibitor-resistant depression. However, the effects of low-dose testosterone as augmentation therapy in women with treatment-resistant depression have not been studied. METHODS: Low-dose transdermal testosterone (300 mcg/day, Intrinsa, Procter and Gamble Pharmaceuticals) was administered to nine women with treatment-resistant depression in an 8 week open-label pilot protocol. RESULTS: There was a statistically significant improvement in mean Montgomery-Asberg Depression Rating Scale (MADRS) scores at 2 weeks, sustained through the 8 week period. Two-thirds of subjects achieved a response to the treatment (decrease in MADRS score of 250%) and 33% achieved remission (final MADRS score <10) after 8 weeks of therapy. Mean levels of fatigue, as measured by the MADRS lassitude item, significantly decreased at all time points with a mean 38% decrease from baseline to 8 weeks. CONCLUSION: These preliminary pilot data suggest that low-dose transdermal testosterone may be an effective augmentation therapy in women with treatment-resistant depression. Further studies are warranted. CNS Spectr. 2009;14(12):688-694
BACKGROUND: Inadequate response to antidepressant monotherapy in women with major depressive disorder is common. Testosterone administration has been shown to be an effective augmentation therapy in depressed hypogonadalmen with selective serotonin reuptake inhibitor-resistant depression. However, the effects of low-dose testosterone as augmentation therapy in women with treatment-resistant depression have not been studied. METHODS: Low-dose transdermal testosterone (300 mcg/day, Intrinsa, Procter and Gamble Pharmaceuticals) was administered to nine women with treatment-resistant depression in an 8 week open-label pilot protocol. RESULTS: There was a statistically significant improvement in mean Montgomery-Asberg Depression Rating Scale (MADRS) scores at 2 weeks, sustained through the 8 week period. Two-thirds of subjects achieved a response to the treatment (decrease in MADRS score of 250%) and 33% achieved remission (final MADRS score <10) after 8 weeks of therapy. Mean levels of fatigue, as measured by the MADRS lassitude item, significantly decreased at all time points with a mean 38% decrease from baseline to 8 weeks. CONCLUSION: These preliminary pilot data suggest that low-dose transdermal testosterone may be an effective augmentation therapy in women with treatment-resistant depression. Further studies are warranted. CNS Spectr. 2009;14(12):688-694
Authors: J L Shifren; G D Braunstein; J A Simon; P R Casson; J E Buster; G P Redmond; R E Burki; E S Ginsburg; R C Rosen; S R Leiblum; K E Caramelli; N A Mazer Journal: N Engl J Med Date: 2000-09-07 Impact factor: 91.245
Authors: C Wang; R S Swerdloff; A Iranmanesh; A Dobs; P J Snyder; G Cunningham; A M Matsumoto; T Weber; N Berman Journal: J Clin Endocrinol Metab Date: 2000-08 Impact factor: 5.958
Authors: Ronald N Marcus; Robert D McQuade; William H Carson; Delphine Hennicken; Maurizio Fava; Jeffrey S Simon; Madhukar H Trivedi; Michael E Thase; Robert M Berman Journal: J Clin Psychopharmacol Date: 2008-04 Impact factor: 3.153
Authors: Maurizio Fava; Michael E Thase; Charles DeBattista; Karl Doghramji; Sanjay Arora; Rod J Hughes Journal: Ann Clin Psychiatry Date: 2007 Jul-Sep Impact factor: 1.567
Authors: Laura E Dichtel; Linda L Carpenter; Maren Nyer; David Mischoulon; Allison Kimball; Thilo Deckersbach; Darin D Dougherty; David A Schoenfeld; Lauren Fisher; Cristina Cusin; Christina Dording; Nhi-Ha Trinh; Paola Pedrelli; Albert Yeung; Amy Farabaugh; George I Papakostas; Trina Chang; Benjamin G Shapero; Justin Chen; Paolo Cassano; Emily M Hahn; Elizabeth M Rao; Roscoe O Brady; Ravinder J Singh; Audrey R Tyrka; Lawrence H Price; Maurizio Fava; Karen K Miller Journal: Am J Psychiatry Date: 2020-07-14 Impact factor: 18.112
Authors: Alexander Behnke; Anja M Gumpp; Aniko Krumbholz; Alexandra M Bach; Gustav Schelling; Iris-Tatjana Kolassa; Roberto Rojas Journal: Compr Psychoneuroendocrinol Date: 2021-06-21